Quick refresher. PD-1 drugs like pembrolizumab work by taking the brakes off T cells, which are your immune system's professional troublemakers in the best possible sense. The problem is that tumors are not just lumps of rogue cells. They are more like sketchy little ecosystems. They recruit helpers, rewrite local rules, and generally turn the neighborhood into a place where immune cells forget how doors work.
One of the biggest accomplices is the tumor-associated macrophage. Macrophages are supposed to be cleanup crews and bodyguards. In cancer, some of them get thoroughly conned and switch sides. Instead of helping immune cells, they calm them down, blunt inflammation, and help tumors keep the lights on. Reviews over the past few years have made the same point again and again: macrophages are a big reason PD-1 therapy can fizzle in solid tumors, including gastric cancer [2-4].
What this study actually showed
The impressive part here is that the researchers did not stop at, "huh, neat correlation." They looked at paired tumor samples from patients before and after treatment in the EPOC1706 trial and tracked what changed [1].
What changed was the macrophage crowd.
Patients whose tumors were packed with these CD206+CD163+ immunosuppressive macrophages were actually more likely to respond to the lenvatinib plus pembrolizumab combo. That sounds backwards for about five seconds. Then it clicks. If the combo is especially good at knocking out that immune-suppressing macrophage population, then tumors that depend on those cells may be especially vulnerable.
The numbers were eyebrow-raising. Eight of nine patients with high infiltration of these macrophages responded to the combination treatment. In contrast, among patients who got PD-1 blockade alone, none of the eight with similarly macrophage-heavy tumors responded [1]. That is not a subtle shrug from biology. That is biology clearing its throat directly into the microphone.
Lenvatinib was not just there for vibes
Lenvatinib is a multitargeted kinase inhibitor, which is a phrase that sounds like it should come with a 43-slide deck and bad coffee. In plainer English, it blocks several signaling pathways tumors and tumor-supporting cells use to survive. This paper suggests that, in these suppressive macrophages, lenvatinib hits PDGFRalpha and FGFR-linked signaling, which then disrupts p38 MAPK and AKT pathways. The result is endoplasmic reticulum stress, an unresolved unfolded protein response, and finally macrophage death [1].
Yes, the paper basically says the drug gives the tumor's corrupt assistants a molecular panic attack.
That matters because it shifts the story from "combo therapies are stronger because more drugs" to "combo therapies can work because one drug removes the immune sabotage that makes the other drug look ineffective." Those are not the same idea, and the second one is far more useful.
Why this matters outside the pathology lab
Gastric cancer still has a nasty habit of outsmarting treatment, and checkpoint inhibitors help only a subset of patients in durable ways [3,4]. Combination therapy has been the obvious next move, but obvious is not the same as elegant. Throwing extra drugs at everyone means more toxicity, more cost, and more chances to discover that cancer did not read the memo.
That is why this macrophage angle is interesting. If these CD206+CD163+ cells really predict who benefits from lenvatinib plus PD-1 blockade, doctors might eventually use them as a biomarker. In other words: not "give the combo to everybody and hope," but "give it to the tumors that are clearly running this macrophage-heavy scam."
There is also an important reality check. Earlier studies made this combo look exciting, and the broader field is still trying to figure out exactly where PD-1 combinations fit best in gastric cancer [4,5]. More recent phase III data have shown that promising biology does not automatically become a clean clinical win for all comers [5]. Cancer, as always, refuses to be normal for even one minute.
Still, this paper gives something the field badly needs: a mechanism and a possible way to choose patients more rationally. That is how cancer therapy gets better. Not by louder hype, but by finding out which cellular weirdos are running the scam and cutting off their badge access.
References
-
Lin NYT, Machiyama H, Kawazoe A, et al. Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation. Cancer Immunol Res. 2025. DOI: https://doi.org/10.1158/2326-6066.CIR-25-0982
-
Chen Y, Song Y, Du W, et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Molecular Cancer. 2023;22:27. DOI: https://doi.org/10.1186/s12943-023-01725-x
-
Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155-170. DOI: https://doi.org/10.1038/s41575-022-00703-w
-
He P, Ma L, Xu B, et al. Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer. Ther Adv Med Oncol. 2024. DOI: https://doi.org/10.1177/17588359241266156
-
Wainberg ZA, Ku G, Tabernero J, et al. Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. J Clin Oncol. 2025. DOI: https://doi.org/10.1200/JCO-25-00748
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.